Executive summary

The whole journey on one page

Ask iZO
DB
Synthetic, de-identified, aggregated data. Illustrative demo.
Executive summary

Why has new-patient growth stalled, and what do we do?

New-patient growth stalled because prescriptions are being lost at prior authorization in two regions, mostly for a missing lab result, while competitors win most late switches. Fixing access in North-East and Mid-South is the fastest lever.

Key findings

  1. 1
    Cohort
    40,000 new RA patients; median age 54; 82.1% biologic-naive.
  2. 2
    Therapy flow
    Switches happen late. Brand X wins 19.7% of line 2 and 3 advanced switches; competitors win 80.3%.
  3. 3
    Drop-off
    27.5% of new prescriptions are abandoned. North-East and Mid-South run 16.7 points above other regions. Top rejection reason: missing lab result.
  4. 4
    Act
    Access to focus on plans in two regions; Field to support 149 flagged practices; Patient Services to add prior auth support.
  5. 5
    Improve
    After the access push, abandonment fell to 23.9% and the regional gap narrowed to 9.9 points.
Abandonment rate by region (%)
Quarterly abandonment and Brand X switch share (%)
Learn and improve.Every data refresh sharpens the next question and the next action.